Biogen
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
BIIB Key Statistics
Stock Snapshot
With a market cap of 30.87B, Biogen(BIIB) trades at $211.13. The stock has a price-to-earnings ratio of 21.37.
On 2026-07-14, Biogen(BIIB) stock traded between a low of $197.74 and a high of $211.13. Shares are currently priced at $211.13, which is +6.8% above the low and 0.0% below the high.
Biogen(BIIB) shares are trading with a volume of 2.26M, against a daily average of 1.4M.
In the last year, Biogen(BIIB) shares hit a 52-week high of $219.72 and a 52-week low of $121.05.
In the last year, Biogen(BIIB) shares hit a 52-week high of $219.72 and a 52-week low of $121.05.
BIIB News
Eisai and Biogen (BIIB) have received U.S. FDA approval for LEQEMBI IQLIK, a once weekly subcutaneous autoinjector initiation dose for early Alzheimer’s. This e...
Jefferies reiterated a Buy rating and $255 price target on Biogen (BIIB) after the FDA approved Leqmbi’s subQ induction ahead of its August 24 PDUFA date. Altho...
As of 11:45 a.m. ET, the S&P 500 (SNPINDEX:^GSPC) fell 0.39% to 7,546.18, the Nasdaq Composite (NASDAQINDEX:^IXIC) slid 0.92% to 26,039.24 on tech weakness, and...
Analyst ratings
61%
of 38 ratingsMore BIIB News
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as...
Jason Zemansky, an analyst from Bank of America Securities, maintained the Hold rating on Biogen. The associated price target remains the same with $217.00. Ti...
Truist upgraded Biogen (BIIB) to Buy from Hold with a $235 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking f...
In the latest look at the underlying components of the S&P 500 ordered by largest market capitalization, NRG Energy Inc (Symbol: NRG) has taken over the #302 sp...
Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Biogen (BIIB) to $222 from $224 and keeps an Equal Weight rating on the shares. Biotech...
Analyst Jason Zemansky of Bank of America Securities reiterated a Hold rating on Biogen, boosting the price target to $217.00. Unlock powerful investing tools...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.